Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials

被引：1
|
作者：
Mellbin, Linda G. [1 ,2 ]
Bhatt, Deepak L. [3 ]
David, Jens-Peter [4 ]
Ekstrom, Kathrine [4 ]
Petrie, Mark C. [5 ]
Rasmussen, Soren [4 ]
Vilsboll, Tina [6 ]
机构：
[1] Karolinska Inst, Dept Med Solna, Eugeniavagen 27, S-17164 Solna, Stockholm, Sweden
[2] Karolinska Univ Hosp, Heart Vasc & Neuro Theme, K2 Med,K2 Kardio Pernow J, S-17177 Solna, Stockholm, Sweden
[3] Mt Sinai Fuster Heart Hosp, Icahn Sch Med Mt Sinai, New York, NY USA
[4] Novo Nord A S, Soborg, Denmark
[5] Univ Glasgow, Sch Cardiovasc & Metab Hlth, Glasgow City, Scotland
[6] Univ Copenhagen, Steno Diabet Ctr Copenhagen, Clin Res, Copenhagen, Denmark
来源：
EUROPEAN HEART JOURNAL | 2024年 / 45卷 / 15期
关键词：
Cardiovascular outcomes trial; Glucagon-like peptide-1 receptor agonist; HbA(1c); Major adverse cardiovascular events; PIONEER; 6; Post hoc analysis; Semaglutide; SUSTAIN; Type; 2; diabetes;
D O I：
10.1093/eurheartj/ehae028
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1371 / 1374
页数：4
相关论文
共 50 条
  • [1] Effect of semaglutide versus placebo on cardiovascular outcomes by baseline HbA1c: SUSTAIN 6 and PIONEER 6 post hoc analysis
    Mellbin, L. G.
    Bhatt, D. L.
    David, J. -P.
    Petrie, M. C.
    Rasmussen, S.
    Schytz, P. A.
    Vilsboll, T.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S304 - S305
  • [2] Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT
    Lingvay, Ildiko
    Deanfield, John
    Kahn, Steven E.
    Weeke, Peter E.
    Toplak, Hermann
    Scirica, Benjamin M.
    Ryden, Lars
    Rathor, Naveen
    Plutzky, Jorge
    Morales, Cristobal
    Lincoff, A. Michael
    Lehrke, Michael
    Jeppesen, Ole Kleist
    Gajos, Grzegorz
    Colhoun, Helen M.
    Cariou, Bertrand
    Ryan, Donna
    DIABETES CARE, 2024, 47 (08)
  • [3] Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6
    Apperloo, Ellen M.
    Cherney, David Z., I
    Kuhlman, Anja Birk
    Mann, Johannes F. E.
    Rasmussen, Soren
    Rossing, Peter
    Tuttle, Katherine R.
    Vrhnjak, Blaz
    Heerspink, Hiddo J. L.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024,
  • [4] Cardiovascular, Metabolic, and Safety Outcomes with Semaglutide by Baseline Age: Post Hoc Analysis of SUSTAIN 6 and PIONEER 6
    Stephen C. Bain
    Nicolas Belmar
    Søren T. Hoff
    Mansoor Husain
    Søren Rasmussen
    Tina Vilsbøll
    Mark C. Petrie
    Diabetes Therapy, 2025, 16 (1) : 15 - 28
  • [5] Semaglutide reduces HbA1c across baseline HbA1c subgroups across SUSTAIN 1-5 clinical trials
    Bain, S. C.
    Araki, E.
    DeSouza, C.
    Garg, S.
    Rose, L.
    Tsoukas, G.
    Bergan, E. Q.
    Karsbol, J. D.
    DeVries, J. H.
    DIABETIC MEDICINE, 2018, 35 : 81 - 81
  • [6] Semaglutide Reduces HbA1c across Baseline HbA1c Subgroups across SUSTAIN 1-5 Clinical Trials
    Bain, Stephen
    Araki, Eiichi
    Desouza, Cyrus
    Garg, Satish
    Rose, Ludger
    Tsoukas, George
    Bergan, Eirik Q.
    Karsbol, Julie Derving
    Devries, J. Hans
    DIABETES, 2017, 66 : A298 - A299
  • [7] Semaglutide reduces HbA1c and body weight across baseline HbA1c subgroups in the SUSTAIN 1-5 clinical trials
    Bain, S.
    Araki, E.
    Desouza, C.
    Garg, S.
    Rose, L.
    Tsoukas, G.
    Bergan, E.
    Karsbol, J. Derving
    DeVries, J.
    DIABETOLOGIA, 2017, 60 : S375 - S375
  • [8] Semaglutide Improves eGFR Slope vs. Placebo Regardless of Baseline HbA1c and Blood Pressure in People With Type 2 Diabetes: A Post Hoc Analysis of SUSTAIN 6 and PIONEER 6
    Cherney, David
    Bosch-Traberg, Heidrun
    Hadjadj, Samy
    Kuhlman, Anja B.
    Rasmussen, Soren
    Tuttle, Katherine R.
    Heerspink, Hiddo J. L.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 675 - 675
  • [9] Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide
    Verma, Subodh
    Fainberg, Udi
    Husain, Mansoor
    Rasmussen, Soren
    Ryden, Lars
    Ripa, Maria Sejersten
    Buse, John B.
    DIABETES OBESITY & METABOLISM, 2021, 23 (07): : 1677 - 1680
  • [10] Cardiovascular, Metabolic and Safety Outcomes With Semaglutide by Age: A Post Hoc Analysis of SUSTAIN 6 and PIONEER 6
    Petrie, Mark
    Bain, Stephen
    Hoff, Soren Tetens
    Johansen, Nicklas
    Rasmussen, Soren
    Vilsboell, Tina
    Husain, Mansoor
    CIRCULATION, 2021, 144
12345